A simple view on lung cancer biology: The MET pathway;Un regard simple sur la biologie du cancer bronchique: MET

Revue des Maladies Respiratoires

Volumn 28, Issue 10, 2011, Pages 1241-1249

  Ruppert, A M ^a   Beau Faller, M ^b   Belmont, L ^a   Lavole A ^a   Gounant, V ^a   Cadranel, J ^a,c   Wislez, M ^a,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Biomarker; MET; Non small lung cancer; Prognosis; Tyrosine kinase inhibitor; Tyrosine kinase receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

CANCER GROWTH; ENZYME ACTIVATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; METASTASIS; ONCOGENE; PROTEIN STRUCTURE; REVIEW;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DISEASE PROGRESSION; ENZYME ACTIVATION; GENE AMPLIFICATION; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; ONCOGENES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84859001239     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.05.014     Document Type: Review

References (41)

1. L. Trusolino A. Bertotti P.M. Comoglio MET signalling: principles and functions in development, organ regeneration and cancer Nat Rev Mol Cell Biol 11 2010 834 848
2. P.M. Comoglio Pathway specificity for Met signalling Nat Cell Biol 3 2001 E161 E162
3. M. Mazzone P.M. Comoglio The Met pathway: master switch and drug target in cancer progression FASEB J 20 2006 1611 1621 (Pubitemid 44943798)
4. C. Quesnel S. Marchand-Adam A. Fabre, et al. Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury Am J Physiol Lung Cell Mol Physiol 294 2008 L334 L343
5. Panganiban RAM, Day RM. Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol. Available from: http://www.ncbi.nlm.nih.gov. gate2.inist.fr/pubmed/21131996 [cité 2010 déc 18].
6. The Human Protein Atlas [Internet]. Available from: http://www. proteinatlas.org/ENSG00000105976/normal [cité 2010 déc 19].
7. H. Ohmichi U. Koshimizu K. Matsumoto, et al. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development Development 125 1998 1315 1324 (Pubitemid 28203946)
8. M. Varella-Garcia Chromosomal and genomic changes in lung cancer Cell Adh Migr 4 2010 100 106
9. L. Schmidt F.M. Duh F. Chen, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 16 1997 68 73 (Pubitemid 27198158)
10. A. Danilkovitch-Miagkova B. Zbar Dysregulation of Met receptor tyrosine kinase activity in invasive tumors J Clin Invest 109 2002 863 867 (Pubitemid 34275106)
11. M. Park M. Dean C.S. Cooper, et al. Mechanism of met oncogene activation Cell 45 1986 895 904 (Pubitemid 16083694)
12. C. Boccaccio P.M. Comoglio Invasive growth: a MET-driven genetic programme for cancer and stem cells Nat Rev Cancer 6 2006 637 645 (Pubitemid 44140861)
13. H. Takeuchi A. Bilchik S. Saha, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases Clin Cancer Res 9 2003 1480 1488 (Pubitemid 36418405)
14. C. Boccaccio G. Sabatino E. Medico, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis Nature 434 2005 396 400 (Pubitemid 40469184)
15. P.C. Ma R. Jagadeeswaran S. Jagadeesh, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res. 65 2005 1479 1488 (Pubitemid 40270177)
16. Y. Nakamura T. Niki A. Goto, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis Cancer Sci. 98 2007 1006 1013 (Pubitemid 46865384)
17. M.S. Tsao N. Liu J.R. Chen, et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers Lung Cancer. 20 1998 1 16 (Pubitemid 28473176)
18. C. To I. Seiden N. Liu, et al. Tsao M-S. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells Exp Cell Res 273 2002 45 53
19. F. Cappuzzo A. Marchetti M. Skokan, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 27 2009 1667 1674
20. P.C. Ma T. Kijima G. Maulik, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions Cancer Res. 63 2003 6272 6281 (Pubitemid 37255174)
21. J.A. Engelman K. Zejnullahu T. Mitsudomi, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science. 316 2007 1039 1043 (Pubitemid 46799492)
22. Z. Tang R. Du S. Jiang, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer Br J Cancer 99 2008 911 922
23. A.Z. Lai J.V. Abella M. Park Crosstalk in Met receptor oncogenesis Trends Cell Biol 19 2009 542 551
24. M. Beau-Faller A.M. Ruppert A.C. Voegeli, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort J Thorac Oncol 3 2008 331 339 (Pubitemid 351489471)
25. J.M. Siegfried J.D. Luketich L.P. Stabile, et al. Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung Chest 125 2004 S116 S119
26. M. Wislez N. Rabbe J. Marchal, et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death Cancer Res 63 2003 1405 1412 (Pubitemid 36348724)
27. D. Masuya C. Huang D. Liu, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients Br J Cancer 90 2004 1555 1562 (Pubitemid 38648238)
28. I. Takanami F. Tanana T. Hashizume, et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers Oncology 53 1996 392 397 (Pubitemid 26283782)
29. R. Navab J. Liu I. Seiden-Long, et al. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells Neoplasia 11 2009 1292 1300
30. S. Yi M.S. Tsao Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line Neoplasia 2 2000 226 234 (Pubitemid 30346078)
31. K. Okuda H. Sasaki H. Yukiue, et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer Cancer Sci 99 2008 2280 2285
32. B. Lutterbach Q. Zeng L.J. Davis, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival Cancer Res. 67 2007 2081 2088 (Pubitemid 46424226)
33. S. Corso C. Migliore E. Ghiso, et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases Oncogene. 27 2008 684 693 (Pubitemid 351158907)
34. Y. Yang M. Wislez N. Fujimoto, et al. A selective small molecule inhibitor of c-Met PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7 2008 952 960
35. T.A. Yap J.S. de Bono Targeting the HGF/c-Met axis: state of play Mol Cancer Ther 9 2010 1077 1079
36. J.P. Eder G.F. Vande Woude S.A. Boerner, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin Cancer Res 15 2009 2207 2214
37. P.M. Comoglio S. Giordano L. Trusolino Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat Rev Drug Discov 7 2008 504 516 (Pubitemid 351767118)
38. Spigel D. Randomized multicenter double-blind placebo-controlled phase 2 study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Program and abstracts of the 35th European Society of Medical Oncology Congress; October 8-12, 2010. Milan, Italy.[Abstract LBA15].
39. Yap TA, Olmos D, Brunetto AT, et al. Phase I: Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. J Clin Oncol. Available from: http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/ 21383285 [cité 2011 mars 18].
40. Sequist L, Akerley W, Brugger W. Final results from ARQ 197-209: a global randomized, placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small-cell lung cancer (NSCLC). Program and abstracts of the 35th European Society of Medical Oncology Congress; October 8-12, 2010; Milan, Italy. Abstract 3630.
41. S. Benvenuti P.M. Comoglio The MET receptor tyrosine kinase in invasion and metastasis J Cell. Physiol 213 2007 316 325 (Pubitemid 47509708)